procedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.

Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation.